

The following is a complete listing of all claims in the application, with an indication of the status of each:

**Listing of claims:**

1. (Original) A fusion peptide comprising,  
a first sequence which promotes translocation of said fusion peptide across a membrane,  
and  
a second sequence that inhibits N-ethylmaleimide sensitive factor (NSF) activity,  
wherein said fusion peptide is SEQ ID NO: 8.

2-5. (Cancel)

6. (Original) The fusion peptide of claim 1, wherein said membrane is an endothelial cell membrane.

7-53. (Cancel)